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Australians, compared with 17% among
other Australians.4 Indigenous lung cancer
patients in the Northern Territory have been
reported to have worse survival than their
non-Indigenous co nterparts.5 Although
reasons for poorer survival have not been








Objective:  To compare survival of Indigenous and non-Indigenous lung cancer patients 
and to investigate any corresponding differences in stage, treatment and comorbidities.
Design and setting:  Cohort study of 158 Indigenous and 152 non-Indigenous patients 
(frequency-matched on age, sex and rurality) diagnosed with lung cancer between 1996 
and 2002 and treated in Queensland public hospitals.
 outcome measures:  Survival after diagnosis of lung cancer; effects of stage at 
osis, treatment, comorbidities and histological subtype on lung cancer-specific 
val.
lts:  Survival of Indigenous lung cancer patients was significantly lower than that of 
Indigenous patients (median survival, 4.3 v 10.3 months; hazard ratio, 1.48; 95% CI, 
1.92). Of 158 Indigenous patients, 72 (46%) received active treatment with 
otherapy, radiotherapy or surgery compared with 109 (72%) of the 152 non-
Indigenous patients, and this treatment disparity remained after adjusting for 
histological subtype, stage at diagnosis, and comorbidities (adjusted risk ratio, 0.65; 95% 
CI, 0.53–0.73). The treatment disparity explained most of the survival deficit: the hazard 
ratio reduced to 1.10 (95% CI, 0.83–1.44) after inclusion of treatment variables in the 
proportional hazards survival model. The remaining survival deficit was explained by the 
higher prevalence of comorbidities among Indigenous cancer patients, mainly diabetes.
Conclusion:  Survival after a diagnosis of lung cancer is worse for Indigenous patients 
than for non-Indigenous patients, and differences in treatment between the two groups 
MJA 2008; 188: 562–566
are mainly responsible.
For editorial comment, see page 560un
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adL g cancer is the commonest cancerong Indigenous Australians. Age-justed incidence is about two times
higher than for non-Indigenous Australians
and age-adjusted mortality is three to four
times higher.1-3 Lung cancer accounts for
27% of all cancer deaths among Indigenous
treatment, later stage at diagnosis or a higher
prevalence of comorbidities such as acute
coronary syndrome or chronic bronchitis.
In this study, we aimed to compare sur-
vival of Indigenous and non-Indigenous
lung cancer patients in Queensland and to
investigate to what extent differences in
treatment, stage at diagnosis and comorbid-
ities might explain any survival gap between
the two groups.
METHODS
This detailed study of lung cancer among
Indigenous patients was nested within a
larger, more general study of the diagnosis,
treatment and survival of all Indigenous
cancer patients compared with non-Indi-
genous patients treated in Queensland pub-
lic hospitals.6 Details of the study design
have been described fully elsewhere.6
Information on all Indigenous people
diagnosed with lung cancer in Queensland
for the 6 years 1997–2002 was obtained
from the Queensland Cancer Registry. This
population-based registry does not collect
information on stage at diagnosis, treat-
ment, or comorbidities, so we obtained this
information through a review of medical
records and linkage to computerised dis-
charge abstracts. Because of legal and
administrative difficulties, patients treated
exclusively in private hospitals were
excluded, as were patients notified only
from a nursing home, pathology laboratory,
or death certificate (Box 1). Because Indi-
genous cancer patients tend to be younger
and more likely to live in rural or remote
areas than non-Indigenous cancer patients,3
we frequency-matched on age and rurality
(using the Accessibility/Remoteness Index
of Australia),7 as well as on sex, to improve
statistical efficiency.8 The medical record
from the largest public hospital at which the
patient received treatment for lung cancer
was reviewed.
All notifications of cancer to the Queens-
land Cancer Registry are checked against
death certificates registered in Queensland,
and interstate deaths of Queensland cancer
patients are identified through the National
Death Index. All lung cancer patients were
followed up for survival for a minimum 12
months until 31 December 2003 unless they
died sooner. Consistent with the often rapid
fatality from lung cancer, the median follow-
up time was 6.4 months. All results presented
here are for lung cancer-specific survival;
results for all-cause survival were similar.
Demographic information and all other
data from the Queensland Cancer Registry
were cross-checked against hospital medical
records and updated where necessary. Stage
at diagnosis was assigned using coding rules
from the Surveillance Epidemiology and End
Results program.9 Basic information on can-
cer treatment, including chemotherapy (yes/
no), radiotherapy (yes/no) and surgery (yes/
no), was collected. Comorbidities and details
of cancer-related surgery were checked
against computerised discharge abstracts.
Statistical analysis
We used proportional hazards survival mod-
els to compare survival for Indigenous and
non-Indigenous lung cancer patients after
accounting for stage at diagnosis, histolo-
gical subtype (small cell and non-small cell),
comorbidities and treatment.
Ethics and community consultation
Ethical clearances were obtained from
Queensland Health, the Queensland Insti-
tute of Medical Research, and all hospitals
that assisted in the data collection (one small
hospital denied access to medical charts).
Throughout the study, the Queensland
Aboriginal and Islander Health Forum acted
as a community resource to provide com-
munity consultation and support.MJA • Volume 188 Number 10 • 19 May 2008
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Over the 6-year study period, there were 180
notifications of Indigenous people with lung
cancer to the Queensland Cancer Registry.
These patients were younger, more likely to
live in rural or remote areas, and more likely
to be economically disadvantaged than the
8718 non-Indigenous people notified to the
registry with lung cancer (Box 2). In con-
trast, method of diagnosis and subtype were
similar between the two groups.
There were 158 Indigenous lung cancer
patients eligible for inclusion (Box 1), and
when frequency-matched to a random
sample of 152 non-Indigenous public-hos-
pital patients, distributions of age, sex,
rurality and economic disadvantage were
similar in the two groups (Box 3). Of the
158 Indigenous (152 non-Indigenous) lung
cancer patients, 137 (122) died during the
study period, and for 128 (110), the under-
lying cause of death was lung cancer.
Method of diagnosis and histological sub-
type of lung cancer were similar for
Indigenous and non-Indigenous patients
(Box 4). A larger percentage of Indigenous
patients had no information about cancer
staging in the chart examined (23% v 13%),
and a smaller percentage had localised dis-
ease (22% v 30%). Chronic bronchitis or
emphysema and diabetes were almost twice
as common among the Indigenous cohort,
but co-occurrence of heart failure, hyperten-
sion and acute coronary syndromes were
similar (Box 5). Fewer than six patients in
each group had chronic renal failure, liver
failure, stroke or dementia.
A smaller percentage of Indigenous than
non-Indigenous patients received chemother-
apy, radiotherapy or surgery (Box 6). There
was a similar pattern for active treatment over-
all. The treatment disadvantage for the
Indigenous cohort remained after adjusting
for histological subtype, stage at diagnosis and
comorbidities: the adjusted risk ratio compar-
ing the percentage of Indigenous and non-
Indigenous patients who received any active
treatment was 0.65 (95% CI, 0.53–0.73).
The median lung cancer-specific survival
for the Indigenous cohort was 4.3 months
(95% CI, 3.1–6.6 months), which was much
shorter than for the non-Indigenous patients
(10.3 months; 95% CI, 7.1–12.6 months).
These disparities were reflected in the unad-
justed hazard rate, which was 48% higher
among Indigenous than non-Indigenous
patients (hazard ratio [HR], 1.48; 95% CI,
1.14–1.92). Because we frequency-matched
the study cohorts, the inclusion of age, sex,
rurality and economic disadvantage made
little difference to the hazard ratio. Similarly,
because histological subtype had a similar
distribution across both cohorts, it made
little difference to the hazard ratio. Although
there were more Indigenous patients who
were not staged (Box 4), and this was related
to worse survival, inclusion of staging in the
model did not change the hazard ratio
appreciably (HR, 1.50; 95% CI, 1.16–1.96).
Fewer Indigenous patients received treat-
ment with chemotherapy, radiotherapy and
surgery (Box 6), and adding these treatment
variables to the proportional hazards sur-
vival model reduced the hazard ratio to 1.10
(95% CI, 0.83–1.44). Addition of comorbidi-
ties (mainly diabetes) further reduced the
hazard ratio to 1.02 (95% CI, 0.77–1.35).
That is, variation in rates of active treatment
accounted for most of the variation in sur-
vival, and concurrent chronic diseases
accounted for the remaining survival differ-
ence between the two groups.
DISCUSSION
We have shown that survival of Indigenous
patients following a diagnosis of lung cancer
is worse than for other Australians because
of treatment differences and, to a lesser
extent, a higher prevalence of comorbidities
such as diabetes.
Our previous study of cancer in general
showed that Indigenous cancer patients had
worse survival than their non-Indigenous
counterparts, but this was not explained by
disparities in cancer treatment, the higher
prevalence of comorbidities, or stage at dia-
gnosis.6 A NT study that examined several
cancers combined, including colorectal,
breast, cervix and lung cancers, also
reported that treatment differences did not
explain all the survival disadvantage of
Indigenous patients.10
Thus, our specific results for lung cancer
survival differ from the results, on average,
for several cancers combined. This might be
because active treatment is especially critical
1 Selection of Indigenous and non-Indigenous patient samples for medical 
record review
* Ineligible because of incorrect date of diagnosis, or treated at the one public hospital that denied access to 
medical records and not treated at any other public hospital. ◆
Indigenous: 180 Non-Indigenous: 8718 
Lung cancer patients, Queensland Cancer Registry, 1997–2002
Not stated: 298 




Nursing home only:  
0  
Private hospital only: 
8 (4.4%) 
Ineligible:* 1 
Indigenous lung cancer patients 
included in the study: 158 




Nursing home only: 
74 (0.8%) 
Private hospital only: 
1848 (21.2%) 
Randomly selected, frequency-matched comparison group: 159 
Ineligible:* 7 
Non-Indigenous lung cancer 
patients included in the study: 152 




Nursing home only: 
4 (1.3%) 
Private hospital only: 
133 (44.6%) 
Indigenous lung cancer 
patients admitted at least 
once for treatment at a 
public hospital: 159 (88.3%) 
Non-Indigenous lung cancer 
patients admitted at least once 
for treatment at a public hospital: 
6473 (74.2%) 
Lung cancer patients (Indigenous 
status not stated) admitted at 
least once for treatment at a 
public hospital: 64 (21.5%)   MJA • Volume 188 Number 10 • 19 May 2008 563
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but less so after the diagnosis of other major
cancers. For instance, there is good evidence
that surgery and radiotherapy for non-small
cell lung cancer improves survival (and
quality of life), and radiotherapy and
chemotherapy optimise survival from small
cell lung cancer.11 In our data, numbers
were too small for a stratified analysis by
subtype, although the subtype distribution
was similar in both cohorts and we adjusted
for subtype in all the models.
Overseas studies of disadvantaged groups
have also found that less active treatment
explains disparities in survival for lung can-
cer.12,13 For example, a study in the United
States of patients with potentially resectable
non-small cell lung cancer (stage I or II)
found that the lower survival of African
American patients, compared with white
patients, was largely explained by lower
rates of surgical treatment.14
Study limitations
Our information on chemotherapy and radio-
therapy was limited to whether it was
received by the patient, because of difficul-
ties associated with obtaining detailed treat-
ment information retrospectively from
medical records. Nevertheless, statistical
adjustment using only the basic treatment
information available removed almost all the
Indigenous survival disadvantage. Also, the
3 Comparison of demographic 







Male 97 (61.4%) 91 (59.9%)
Female 61 (38.6%) 61 (40.1%)
Age (years): 
median (IQR)
63 (53–70) 64 (54–71)
Rurality: no. (%)
Capital city 34 (21.5%) 44 (29.0%)
Regional cities 49 (31.0%) 38 (25.0%)
Rural/remote 75 (47.5%) 70 (46.1%)
Economic disadvantage:* no. (%)
Disadvantaged 25 (15.8%) 19 (12.5%)
Intermediate 132 (83.6%) 131 (86.2%)
Affluent 1 (0.7%) 2 (1.3%)
IQR = interquartile range. *  Based on the Index of 
Economic Disadvantage from the Australian 
Bureau of Statistics’ Socio-Economic Index for 
areas (SEIFA) Small Areas. ◆
2 Characteristics of Indigenous and non-Indigenous patients diagnosed with 
lung cancer, 1997–2002, Queensland
Indigenous Non-Indigenous Not stated Total
No. of lung cancer patients 
(% of total)
180 (2.0%) 8718 (94.8%) 298 (3.2%) 9196 (100.0%)
Sex: no. (%)
Male 115 (63.9%) 6004 (68.9%) 169 (56.7%) 6288 (68.4%)
Female 65 (36.1%) 2714 (31.1%) 129 (43.3%) 2908 (31.6%)
Age (years): median (IQR) 63 (53–71) 70 (62–76) 69 (60–76) 70 (61–76)
Rurality: no. (%)
Capital city 43 (23.9%) 5759 (66.1%) 214 (71.8%) 6016 (65.4%)
Regional cities 54 (30.0%) 1297 (14.9%) 33 (11.1%) 1384 (15.1%)
Rural/remote 83 (46.1%) 1662 (19.1%) 51 (17.1%) 1796 (19.5%)
Economic disadvantage:* no. (%)
Disadvantaged 34 (18.9%) 790 (9.1%) 14 (4.7%) 838 (9.1%)
Intermediate 145 (80.6%) 7543 (86.5%) 263 (88.3%) 7951 (86.5%)
Affluent 1 (0.6%) 385 (4.4%) 21 (7.1%) 407 (4.4%)
Method of diagnosis: no. (%)
Microscopy of primary 124 (68.9%) 6134 (70.4%) 217 (72.8%) 6475 (70.4%)
Histology of metastases 15 (8.3%) 730 (8.4%) 16 (5.4%) 761 (8.3%)
Clinical 33 (18.3%) 1551 (17.8%) 48 (16.1%) 1632 (17.7%)
Death certificate only 8 (4.4%) 303 (3.5%) 17 (5.7%) 328 (3.6%)
Subtype: no. (%)
Non-small cell 112 (64.4%) 5061 (61.2%) 170 (60.3%) 5343 (61.2%)
Small cell 25 (14.4%) 1118 (13.5%) 18 (6.4%) 1161 (13.3%)
Other (specified) 1 (0.6%) 129 (1.6%) 27 (9.6%) 157 (1.8%)
Not specified 36 (20.7%) 1964 (23.7%) 67 (23.8%) 2067 (23.7%)
IQR = interquartile range. * Based on the Index of Economic Disadvantage from the Australian Bureau of 
Statistics’ Socio-Economic Index for areas (SEIFA) Small Areas. ◆






ratio* (95% CI)† P
Method of diagnosis: no. (%)
Microscopy of primary 113 (71.5%) 113 (74.3%) 1.00
Histology of metastases 16 (10.1%) 14 (9.2%) 1.13 (0.57–2.21) 0.73
Clinical 29 (18.4%) 25 (16.4%) 1.13 (0.70–1.82) 0.63
Subtype: no. (%)
Non-small cell lung cancer 101 (63.9%) 91 (59.9%) 1.00
Small cell lung cancer 23 (14.6%) 23 (15.1%) 0.92 (0.55–1.54) 0.75
Other (specified) 1 (0.6%) 3 (2.0%) 0.31 (0.03–2.90) 0.27
Not specified 33 (20.3%) 35 (23.0%) 0.89 (0.59–1.33) 0.56
Spread of disease at diagnosis: no. (%)
Localised 34 (21.5%) 45 (29.6%) 1.00
Regional 33 (20.9%) 33 (21.7%) 1.16 (0.82–1.66) 0.40
Distant 54 (34.2%) 54 (35.5%) 1.13 (0.88–1.44) 0.35
Not stated in medical record 37 (23.4%) 20 (13.2%) 1.69 (1.10–2.60) 0.01
* Risk ratios greater than 1.0 mean that the characteristic is more common in the Indigenous cohort and risk 
ratios less than 1.0 mean that it is less common. † Exact 95% confidence interval. ◆564 MJA • Volume 188 Number 10 • 19 May 2008
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ing surgery (10%) was the same as that
reported in Western Australia.15
We found that 23% of Indigenous patients
and 13% of non-Indigenous patients did not
have any information in the particular medi-
cal record examined about spread of the lung
cancer at the time of diagnosis. We did not
exclude these patients from our analysis, but
statistically adjusted for the “not staged” cat-
egory as well as “distant”, “regional” and
“localised” categories. Moreover, the rela-
tively high percentage of Indigenous patients
with no staging information is an important
finding in itself. For both small cell and non-
small cell lung cancer, outcomes are
improved if the patient’s cancer is staged.11
Indigenous patients may have poorer per-
formance status or lung function than non-
Indigenous patients, but we did not have
information on these possibly important con-
founders. This may have explained, at least in
part, their lower rates of cancer treatment; for
example, if some of the Indigenous patients
were otherwise too sick for active cancer
treatment. However, after adjustment for
comorbidities affecting performance status
and lung function, the percentage of Indi-
genous patients who did not receive active
treatment was still 35% lower than in non-
Indigenous patients.
Finally, Indigenous identification in the
Queensland Cancer Registry and computer-
ised discharge abstracts is based on self-
identification6 (as in all routine datasets in
Australia). Because Indigenous status has
been routinely collected in Queensland hos-
pitals since 1996, case ascertainment should
be reasonably complete. Moreover, we
believe our Indigenous to non-Indigenous
comparisons to be internally valid with little
misclassification of ethnicity, as medical
charts were examined for verification.
Implications for delivery of health 
services
Other research groups have suggested a link
between specialist referral and active treat-
ment of lung cancer. For example, one of
the reasons suggested for the lower survival
from lung cancer in the United Kingdom
compared with other European countries
was poorer access to specialised care
because of fewer consultants per head of
population.16 Similarly, a population-based
patterns-of-care study in the United States
found that whether patients received chemo-
therapy for lung cancer was determined by
whether they were seen by a specialist.17







ratio* (95% CI)† P
Chronic bronchitis or emphysema
No 99 (62.7%) 120 (79.0%) 1.00
Yes 59 (37.3%) 32 (21.0%) 1.77 (1.23–2.56) 0.002
Heart failure
No 118 (74.7%) 111 (73.0%) 1.00
Yes 40 (25.3%) 41 (27.0%) 0.94 (0.65–1.36) 0.74
Diabetes
No 133 (84.2%) 139 (91.5%) 1.00
Yes 25 (15.8%) 13 (8.6%) 1.85 (0.98–3.48) 0.05
Hypertension
No 141 (89.2%) 135 (91.5%) 1.00
Yes 17 (10.8%) 17 (11.2%) 0.96 (0.51–1.81) 0.91
Ischaemic heart disease
No 142 (89.9%) 136 (89.5%) 1.00
Yes 16 (10.1%) 16 (10.5%) 0.96 (0.50–1.85) 0.91
Chronic renal failure
No 154 (97.5%) 150 (98.7%) 1.00
Yes 4 (2.5%) 2 (1.3%) 1.92 (0.36–10.35) 0.44
Past stroke
No 156 (98.7%) 146 (96.0%) 1.00
Yes 2 (1.3%) 6 (4.0%) 0.32 (0.07–1.56) 0.14
Chronic liver failure
No 156 (98.7%) 151 (99.3%) 1.00
Yes 2 (1.3%) 1 (0.7%) 1.92 (0.18–21.0) 0.59
Dementia
No 158 (100.0%) 151 (99.3%) 1.00
Yes 0 1 (0.7%) 0 (39.8‡) 0.31
* Risk ratios greater than 1.0 mean that the characteristic is more common in the Indigenous cohort and risk 
ratios less than 1.0 mean that it is less common. † Exact 95% CI. ‡  Upper bound. ◆






Unadjusted risk ratio* 
(95% CI)† P
Chemotherapy
No 138 (87.3%) 110 (72.4%) 1.00
Yes 20 (12.7%) 42 (27.6%) 0.46 (0.28–0.74) 0.001
Radiotherapy
No 109 (69.0%) 87 (57.2%) 1.00
Yes 49 (31.0%) 65 (42.8%) 0.73 (0.54–0.98) 0.03
Surgery
No 142 (89.9%) 113 (74.3%) 1.00
Yes 16 (10.1%) 39 (25.7%) 0.39 (0.23–0.68) < 0.001
Any active treatment‡
No 86 (54.4%) 43 (28.3%) 1.00
Yes 72 (45.6%) 109 (71.7%) 0.64 (0.52–0.77) < 0.001
*Risk ratios less than 1.0 mean that the characteristic is less common in the Indigenous cohort. †Exact 95% CI. 
‡ Active treatment was any chemotherapy, radiotherapy or surgery at any stage of the patient’s illness.  ◆MJA • Volume 188 Number 10 • 19 May 2008 565
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whether patients were referred for a special-
ist opinion. It would be useful to determine
whether Indigenous lung cancer patients are
less likely to consult a lung cancer specialist
than non-Indigenous patients, and to inves-
tigate who makes this decision — the
patient or the general practitioner. Also,
studies in other settings have suggested that
some patients (and their doctors) take an
overly fatalistic attitude to lung cancer,
which means that the patients receive less
than optimal treatment and their quality of
life and survival is less than it otherwise
might have been.18 This would also be a
useful avenue for further investigation.
Indigenous lung cancer patients have par-
ticular needs that should be explicitly con-
sidered when planning cancer services. For
example, they often need to travel long
distances to access specialist services, and
they may have particularly fatalistic views of
lung cancer and its treatment. Although
further research is needed, sensible policy
initiatives could be implemented immedi-
ately given the seriousness of the problem.
Initiatives could be evaluated while they are
being implemented — an approach that
encourages creativity and innovation,18 and
would contribute valuable evidence for
refining subsequent initiatives.
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